Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 10/20 | 0.53 |
| ▸ | NOS1 | P29475 | 10/20 | 0.51 |
| ▸ | NOS3 | P29474 | 6/20 | 0.51 |
| ▸ | NOS2 | P35228 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL222345 | 0.87 | NCF1 (0.50) | NCF1NOS1NOS3NOS2 | |
| SCHEMBL4284903 | 0.86 | NOS1 (0.54) | NOS1NOS3NOS2 | |
| SCHEMBL4282766 | 0.85 | NOS1 (0.53) | NOS1NOS3NOS2 | |
| SCHEMBL221742 | 0.83 | NOS1 (0.51) | NOS1NOS3NOS2 | |
| SCHEMBL222693 | 0.83 | NOS1 (0.73) | NOS1NOS3NOS2 | |
| SCHEMBL221420 | 0.83 | NOS1 (0.48) | NCF1NOS1NOS3NOS2 | |
| SCHEMBL221914 | 0.80 | NOS3 (0.63) | NOS1NOS3NOS2 | |
| SCHEMBL252012 | 0.80 | NOS1 (0.49) | NOS1NOS3NOS2 | |
| SCHEMBL6585074 | 0.79 | ACACA (0.50) | NOS1NOS3 | |
| SCHEMBL6583956 | 0.78 | NOS1 (0.48) | NOS1NOS3NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040229911-A1 | New pharmaceutical combinations for NOS inhibitors | PFIZER INC | 2004-11-18 | — | — | US | claimed |
| JP-2003523941-A | — | — | 2003-08-12 | — | — | JP | claimed |
| US-20030045449-A1 | Pharmaceutical combinations for the treatment of neurodegenerative diseases | PFIZER, INC. | 2003-03-06 | — | — | US | claimed |
| EP-1178784-A1 | NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS | Pfizer Products Inc. (US) | 2002-02-13 | — | — | EP | claimed |
| WO-2000071107-A2 | NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-11-30 | — | — | WO | claimed |
| WO-2018033639-A1 | LACTONE INTERMEDIATES OF NICOTINAMIDE RIBOSIDE AND NICOTINATE RIBOSIDE | THE QUEEN'S UNIVERSITY OF BELFAST (GB) | 2018-02-22 | — | — | WO | disclosed |
| WO-2009158646-A1 | THERAPEUTIC COMPUNDS AND RELATED METHODS OF USE | ELIXIR PHARMACEUTICALS, INC. (US) | 2009-12-30 | — | — | WO | disclosed |
| US-20040229911-A1 | New pharmaceutical combinations for NOS inhibitors | PFIZER INC | 2004-11-18 | — | — | US | disclosed |
| EP-0958282-B1 | 2-AMINO-6-(2-SUBSTITUTED-4-PHENOXY)-SUBSTITUTED-PYRIDINES | PFIZER PROD INC (US) | 2004-07-21 | — | — | EP | disclosed |
| US-20030162765-A1 | Use in treatment and prevention of central nervous system and other disorders | PFIZER INC. | 2003-08-28 | — | — | US | disclosed |
| EP-1178784-A1 | NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS | Pfizer Products Inc. (US) | 2002-02-13 | — | — | EP | disclosed |
| US-20010007873-A1 | Compounds such as 4-(6-amino-pyridin-2-yl)-3-methoxyphenol as nitric oxide synthase inhibitors used to treat central nervous system disorders, inflammatory disorders, septic shock, etc... | PFIZER INC. | 2001-07-12 | — | — | US | disclosed |
| WO-2000071107-A2 | NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045449-A1 | Pharmaceutical combinations for the treatment of neurodegenerative diseases | GRIN3A, GRIN1, CHRNA10 | NCF1 1492/4885NOS1 110/4885NOS3 157/4885 |
| US-20010007873-A1 | Compounds such as 4-(6-amino-pyridin-2-yl)-3-methoxyphenol as nitric oxide synthase inhibitors used to treat central nervous system disorders, inflammatory disorders, septic shock, etc... | NOS1, PTGS1, NOS2 | NCF1 1776/4885NOS1 1/4885NOS3 4/4885 |
| US-20040229911-A1 | New pharmaceutical combinations for NOS inhibitors | NOS1, NOS3, NPBWR1 | NCF1 481/4885NOS1 1/4885NOS3 2/4885 |
| US-20030162765-A1 | Use in treatment and prevention of central nervous system and other disorders | GRIN2C, GRIN2A, CNR2 | NCF1 3808/4885NOS1 2484/4885NOS3 2496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.